Navigation Links
Bioclinica Medical Imaging Achieves Milestone with Celebration of Primary Endpoint Data Analysis Contributions to 200 FDA Approvals
Date:11/14/2019

Bioclinica Medical Imaging, the world leader in centralized imaging services for clinical trials, announced today that it has reached a milestone in the company’s history: the company has contributed reliable data to the primary efficacy endpoint in more than 200 regulatory submissions from biopharmaceutical clients for therapies and indications subsequently approved by the U.S. Food and Drug Administration.

“At Bioclinica, we are proud to have played a part in helping our clients assess the safety and efficacy of new treatments that improve people’s lives,” said David Herron, President & CEO of Bioclinica. “We are grateful to our scientific and project teams, and to all the patients and their families who participated in the clinical studies.”

Bioclinica provides science and technology expertise to assist the life science industry in advancing the development of medical therapies through services in Medical Imaging, Drug Safety Solutions, and Software Solutions. Bioclinica Medical Imaging provides comprehensive support across multiple therapeutic areas, with particular expertise in oncology, musculoskeletal, cardiovascular, gastrointestinal, neuroscience, endocrinology, infectious and respiratory disease.

“Every day, Bioclinica’s team of professionals works to ensure the quality and integrity of the data we process, ensuring that our clients and regulatory authorities have information they can rely upon to evaluate the safety and efficacy of investigational treatments,” said Todd Kisner, Senior Vice President, Quality Assurance & Regulatory Compliance. “We look forward to continuing to partner with the biopharmaceutical industry as the pace of innovation accelerates and the demand for high-quality image and clinical data analysis combined with regulatory expertise increases.”

About Bioclinica
Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company's thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

Learn more about Bioclinica at http://www.Bioclinica.com. Follow the latest company news and happenings on LinkedIn and Twitter.

Read the full story at https://www.prweb.com/releases/bioclinica_medical_imaging_achieves_milestone_with_celebration_of_primary_endpoint_data_analysis_contributions_to_200_fda_approvals/prweb16723780.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Grunenthal Expands Use of BioClinicas Next Generation Trident IWR/IVR for Global Trial
2. BioClinica Announces Innovative Big Data Research Project
3. BioClinica Opens Research Triangle Park Office
4. BioClinica and Kinapse Partner to Accelerate Risk-Based Monitoring Implementation
5. BioClinica Acquires MediciGroup
6. BioClinica übernimmt MediciGroup
7. BioClinica Launches eHealth Cloud
8. BioClinica startet eHealth Cloud
9. Bioclinica Launches NAFLD/NASH Clinical Trials Practice
10. Vasomedical Announces Financial Results for the First Quarter of 2013
11. CCS Medical Moves Forward as Medicare Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
(Date:12/2/2019)... ... December 02, 2019 , ... A ... for Michael, an intensive mental health facility, announced it has named Tim Ryan ... business development and national advocacy efforts. , "We are proud to announce that ...
(Date:12/2/2019)... ... December 02, 2019 , ... ... places to live, work, learn, and play. Striving to fulfill their crucial mission, ... rigorous national standards set by the Public Health Accreditation Board (PHAB). Today, PHAB ...
Breaking Medicine Technology:
(Date:12/4/2019)... ... December 04, 2019 , ... Eolas Therapeutics Inc. today ... use and dependence. The study will investigate safety and pharmacokinetics (PK) of AZD4041 ... orexin-1 (hypocretin-1) receptors that is being developed in collaboration with AstraZeneca. , “Smoking-related ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... solutions, has worked with EMD Serono, the North American branch of the healthcare ... . This site is designed to educate and inform patients, caregivers, the public, ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... efficiency and flexibility to the Sterile Processing Department. The elegant design provides a ... The P1000 has downward sliding doors that allow for manual loading that provides ...
(Date:11/30/2019)... ... November 28, 2019 , ... Planet 13 , a ... and dispensary operations, has received a Clio Cannabis Award in Brand Design for ... great accomplishment for our company and also for the talented creative team who ...
(Date:11/30/2019)... ... November 29, 2019 , ... As Cumberland ... teachers aren’t focusing on the potential for academic backslide but rather opportunities for ... textbooks or logging into GoogleClassroom as often during the break but might be ...
Breaking Medicine News(10 mins):